STAT April 22, 2024
Meghana Keshavan

Morning! Hope you had a delightful weekend. Up today: an exclusive look at the scientific mix-up behind the approval of preterm birth drug Makena. We hear from a mother of a son with Duchenne muscular dystrophy who wants to ensure the FDA’s accelerated approval pathway stays strong, and more.

The mix-up behind a controversial drug for preterm...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma, Pharma / Biotech
BridgeBio, Ipsen, George Medicines and more—Chutes & Ladders
Weight loss drugs and stomach paralysis: New findings
A closer look at 2023's top biopharma deals and what lies ahead
Gene Therapy Allowing Heart to Grow New Blood Vessels Supported by Early Data
Amid buzz for Amgen's obesity drug, company sees revenue boost

Share This Article